SOLICITATION NOTICE
B -- Professional Services
- Notice Date
- 10/7/2010
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-PB-(DE)-2011-004-CRS
- Archive Date
- 10/27/2010
- Point of Contact
- Caitlin Savina, Phone: 3014350365
- E-Mail Address
-
savinacr@nhlbi.nih.gov
(savinacr@nhlbi.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSALS. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. It is the intent of the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) on behalf of the National Institute of Dental and Craniofacial Research (NIDCR) to negotiate/award a purchase order on a noncompetitive sole source basis to Zhennan Lai, 2 Boat House Court, Gaithersburg, MD 20878 for the purchase of professional consulting services. The reference number NHLBI-PB-(DE)-2011-004-CRS. This procurement of professional services is to perform, prepare, and analyze samples from Sjogren’s patients using microarray technologies. Primary Sjogren’s Syndrome (SS) is a systemic autoimmune disorder characterized by exocrine gland dysfunction primarily involving the salivary and lacrimal gland. The histologic hallmark of Sjogren’s Syndrome is a periductal inflammatory infiltrate. The conventional explanation of salivary gland dysfunction assumes a causal relationship between this chronic inflammatory process and the decreased saliva production is limited. Moreover, anti-inflammatory and immunosuppressive treatments have little effect on saliva production. Although various physiologic abnormalities related to inflammatory mediators have been described, none of these satisfactorily explains the SG dysfunction. On the other hand, no study has addressed whether patients with Sjogren’s Syndrome have any intrinsic abnormalities in the salivary gland that may predispose them to SG dysfunction. In this study, NIDCR plans to identify any salivary gland abnormalities that may predispose to Salivary Gland dysfunction in Sjogren’s Syndrome patients. To explore if the striking female predominance of SS can be explained by intrinsic differences in salivary glands, we will compare the gene expression profiles of healthy men and woman as well as mouse models of the disease. This approach may identify abnormalities that are either intrinsic to the salivary gland (male to female and normal to SS comparison) or are important in the chronic inflammatory process (normal looking cells vs. cells from infiltrate). The sole source determination is based on the fact that Dr. Zhennan Lai has the background, knowledge, and experience needed for this research project. Dr. Lai’s extensive background in microarray technology to develop new (DNA/Protein) micro-tip (array) technique (manual and automation) for use in the diagnosis detection of mutation/SNP site on genetic neurological disorders, such as N370S type-1 Gaucher disease (GD) and also in monitoring patient response to treatment. Dr Lai received his Ph.D. in Pharmaceutical Science from the University of Uppsala in Sweden in 1994 and has eight years experience in the field of molecular biology performing genetic analysis using the latest microarray technology. He has worked in the industry as a Research Scientist for PDD Biotech, Inc. to develop novel technology that follows changes in genes expression. He is named as an inventor on patent application No. 60/738,974 regarding the use of genetic biomarkers for neurometabolic disorders, which is applicable to NIDCR’s needs on this research project in Sjogren’s Syndrome. Dr. Lai’s background and experience meet the needs of NIDCR’s current research project as a contractor. This acquisition is being conducted under FAR Part 13, Simplified Acquisition Procedures, and is exempt from the requirements of FAR Part 6, Competition Requirements. This is a small business set-aside. The North American Industry Classification System (NAICS) Code is 541990 and the business size standard is $7.0M. This notice of intent is not a request for competitive proposals. The determination by the Government not to compete the proposed purchase order based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing synopsis number NHLBI-PB-(DE)-2011-004-CRS may be submitted by mail to the National Heart, Lung and Blood Institute, Office of Acquisitions, Procurement Branch, 6701 Rockledge Drive, Suite 6150B, Bethesda, MD 20892-7902, Attention: Caitlin Savina, by fax transmission to (301)480-3345 or by email to savinacr@nhlbi.nih.gov This action is under the authority of 41.U.S.C.253(c)(1), as set forth in FAR 13.106(b)(2), and HHSAR 306-302-1. Parties responding to this announcement need to do so by 8:00am Eastern Standard Time on October 12, 2010.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-PB-(DE)-2011-004-CRS/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02308257-W 20101009/101007234443-d76e8d6b3e0f5568461905654eef3576 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |